The
potential for Seroptix's Spectra-Molecular Informatics
platform goes far beyond its current application for the identification
of molecular markers of infectious disease. The Company believes
that the SMI approach can be effectively applied to any disease,
and based on the initial success of our early studies with HCV,
we plan to aggressively expand the application of SMI to a number
conditions where additional diagnostic markers and therapeutic
targets would have particular clinical value.
Medical applications will include the parallel identification
of new markers for several cancer types, neurological diseases,
heart disease, and other selected conditions.
Similarly, the direct detection and analysis of intrinsic fluorescence,
as performed by the Seroptix INFLIT
systems, has important applications beyond disease marker identification.
The company intends to evaluate its technologies as rapid assays
for the direct detection of diseases. A specific optimized device
could be designed to magnify and rapidly assess the subtle signatures
associated with a specific disease that are determined by the
SMI approach.
In addition to its medical applications, these powerful technologies
can be useful in other industries such as veterinary science,
food and beverage quality control, chemical contaminant analysis,
and the characterization and detection of biological and chemical
weapons, which the company intends to investigate as alternative
product opportunities.
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
